Subscribe to Newsletter

Queenie Jang

Chief Executive Officer, International Society for Cell & Gene Therapy

For Jang, the emergence of the advanced medicine field is akin to evolution from analogue to digital platforms in the IT sector. She also believes that cost-of-goods optimization is key to broad healthcare adoption of ATMPs.

What one thing do you think could improve the pharma industry?

One thing that could improve pharma in the CGT sector, as witnessed in the evolution of peptide and protein therapy, is to work carried out by CGT academia and the CGT enabling/developer industry to solve substantial manufacturing challenges for CGTs, in order to reduce the cost of these therapies and thus increase patient access and reimbursement globally.

If you weren’t in the pharma industry, what would you be doing?

Semi-retired and learning cooking techniques. With technique and creativity combined, innovation is limitless.

Part of the Power List 2020

The Power List 2020

Celebrating the great minds that bring us innovation in small molecules, biopharmaceuticals, and advanced medicine.

Go to The Power List 2020

Part of the Power List 2021

Find out more

Welcome to our annual celebration of the great and inspirational minds that contribute to the development and manufacture of new medicinal products

Go to The Power List 2021

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine